Related Experiment Video
Updated: Jul 18, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case
Zhongfu Cai1, Jishui Huang, Wenliang Dai
1Department of Respiratory and Critical Care Medicine, The Hospital of Nan'an, Quanzhou, China.
Rationale:
Radical surgery offers the best chance of cure, it is critical to expand surgery opportunities for patients with early-stage lung cancer to prolong overall survival. However, evidence is still limited regarding the application of neoadjuvant therapy with EGFR-tyrosine kinase.
Patient:
The patient reported here was a 53-year-old woman with right lower lung adenosquamous carcinoma.
Diagnoses:
The lung cancer was staged as T3N1M0. Tumor genotype disclosed EGFR Exon19 c.2235-2249de p.E746-A750del.
Intervention:
After neoadjuvant treatment with icotinib, she underwent thoracotomy and achieved pathological complete response.
Outcomes:
She is currently receiving adjuvant icotinib therapy without recurrence or metastasis during 18-month follow-up.
Lessons:
Our case indicated that the feasibility of neoadjuvant icotinib in EGFR-mutant lung adenosquamous carcinoma.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
